pone.0211564.g003.tif (1.67 MB)

Increased expression of AZIN2 follows the induction of EMT in HT-29 cells.

figure

posted on 2019-02-15, 18:25 authored by Tuomas Kaprio, Tiina Rasila, Jaana Hagström, Harri Mustonen, Petri Lankila, Caj Haglund, Leif C. Andersson

HT-29 cells (a) after treatment with TGFβ+TNFα for 48 h (b) show upregulated expression of AZIN2 transcript (c) and AZIN2 protein (d). Panel c shows the results of four RT-qPCR experiments with error bars indicating SD. Panel d shows Western blotting with K3 antibodies.

History

Usage metrics

Read the peer-reviewed publication

Ornithine decarboxylase antizyme inhibitor 2 (AZIN2) is a signature of secretory phenotype and independent predictor of adverse prognosis in colorectal cancer

PLOS ONE

Categories

Keywords

5- year disease-specific survival rate AZIN 2 cDNA colorectal cancer Ornithine decarboxylase histological tumor grade High tumor expression ODC antizyme inhibitors CD 63-positive exosomes Cox multivariable analysis intracellular vesicle transport AZIN 2 expression T 84 CRC cells EMT-associated secretory phenotype AZIN 2 Ornithine decarboxylase antizyme inhibitor 2 HT -29 CRC cells

Licence

Exports